Comparison between washed microbiota transplantation and infliximab: Medical cost during long-term management in patients with inflammatory bowel disease

• Published in: Journal of the Chinese Medical Association Vol. 87; no. 1; pp. 109 - 118
• Main Authors: Zhang, Sheng, Huang, Yihao, Lu, Gaochen, Zhang, Zulun, Wang, Yun, Liu, Yujie, Wang, Weihong, Li, Qianqian, Li, Pan, Wen, Quan, Cui, Bota, Zhang, Faming
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2024
• Subjects: Hospitalization; Humans; Inflammatory Bowel Diseases - chemically induced; Inflammatory Bowel Diseases - therapy; Infliximab - adverse effects; Infliximab - therapeutic use; Mesalamine; Microbiota
• ISSN: 1726-4901; 1728-7731
• DOI: 10.1097/JCMA.0000000000001025

Both infliximab (IFX) and fecal microbiota transplantation (FMT) have shown the efficacy for inflammatory bowel disease (IBD). However, there has no head-to-head study on the cost-value of the such treatments on IBD. This study aimed to compare the medical costs using IFX and the new method of FMT (washed microbiota transplantation [WMT]) in the long-term management for IBD under the current health economic condition in China. Patients with IBD who underwent initial WMT via upper gastrointestinal endoscopy, mid-gut tube, or colonic transendoscopic enteral tubing at a university hospital between April 2013 and August 2021 and achieved the long-term sustainment with WMT or WMT combined with mesalazine until August 2022 were recruited in the real-world. The costs and hospitalizations were analyzed among two therapies mentioned above and IFX standard therapy. The charge of WMT was stable in the long term at our center, and the charge of IFX came from virtual statistics publicized by China Healthcare Security. Sixty eligible patients with IBD were included in the study. The long-term costs of patients using WMT monotherapy annually or per hospitalization were lower than those on WMT combined with mesalazine, respectively ( p < 0.001, respectively). The cumulative costs of IFX at the time of 0.52 and 0.85 years exceeded that of the above WMT, respectively ( p < 0.001, respectively). Besides, patients on WMT monotherapy paid 51.1 k CNY annually in the nonsustain phase but cut down the costs by 7.2 k CNY and duration of hospitalization by 5.1 days per hospitalization when reaching the goal of sustainment. This study demonstrated that WMT could dramatically reduce the cost and duration of hospitalizations in the long-term sustainment in the current Chinese IBD cohort. Compared with IFX, WMT could be a good way for the patients with IBD achieving long-term sustainment and saving medical costs.